Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
306
Recruiting, any sponsor type, condition "stroke"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting306
- Completed1,013
306 trials
Showing 1 to 25, recently updated first.
- Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation TherapyPivotal-lookingRecruiting
Insel Gruppe AG, University Hospital BernAcademic, hospital or other
NCT05976685 · 482 participants (planned) · Start May 1, 2024 · Primary completion Jan 1, 2028
Drug: DOAC · For: Ischemic Stroke; Atrial Fibrillation
Sites: Bruges, Belgium; Brussels, Belgium; Charleroi, Belgium · 35 sites in all
POLYSAN Scientific & Technological Pharmaceutical CompanyIndustry
NCT06514976 · 562 participants (planned) · Start Mar 1, 2024 · Primary completion Jun 1, 2027
Drug: Cytoflavin · For: Stroke, Acute; Stroke, Ischemic
Sites: Ivanovo, Russia; Kazan', Russia; Moscow, Russia · 17 sites in all
- Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling DeficitsPivotal-lookingRecruiting
Shandong Provincial HospitalGovernment (non-federal)
NCT07944261 · 1,324 participants (planned) · Start Oct 15, 2026 · Primary completion Apr 2029
Drug: Tenecteplase 0.18 mg/kg; Tenecteplase 0.25 mg/kg · For: Acute Ischemic Stroke; Minor Ischemic Stroke
Sites: Jinan, China
Washington University School of MedicineAcademic, hospital or other
NCT07916883 · 30 participants (planned) · Start Nov 18, 2026 · Primary completion May 31, 2027
Drug: 64Cu-NODAGA-CANF; Optimal Medical Therapy (OMT) · For: Carotid Atherosclerosis; Carotid Artery Stenosis Asymptomatic; Asymptomatic Carotid Artery Stenosis
Sites: Los Angeles, California; St Louis, Missouri
- Cilostazol for Prevention of Recurrent Stroke TrialPivotal-lookingRecruiting
Stanford UniversityAcademic, hospital or other
NCT07174414 · 2,000 participants (planned) · Start Oct 15, 2026 · Primary completion Jul 2031
Drug: Cilostazol 100 mg Tablets; Placebo · For: Stroke Recurrence; Myocardial Infarction; Vascular Death and 4 more
Sites: Birmingham, Alabama; Chandler, Arizona; Fontana, California · 54 sites in all
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07626411 · 15,364 participants (planned) · Start Aug 10, 2026 · Primary completion Sep 11, 2029
Drug: REGN7508; Apixaban and 1 more · For: Atrial Fibrillation (AF)
Sites: Alexander City, Alabama; Dothan, Alabama; Fairhope, Alabama · 84 sites in all
- BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral AtherosclerosisPivotal-lookingRecruiting
Yonsei UniversityAcademic, hospital or other
NCT07237308 · 586 participants (planned) · Start Jul 14, 2026 · Primary completion Jul 1, 2029
Drug: Apixaban; Clopidogrel · For: Stroke; Ischemic; Atrial Fibrillation and 2 more
Sites: Busan, South Korea; Chuncheon, South Korea; Daegu, South Korea · 21 sites in all
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitablePivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07430956 · 2,628 participants (planned) · Start Apr 3, 2026 · Primary completion Mar 28, 2029
Drug: REGN7508; REGN9933 and 1 more · For: Atrial Fibrillation (AF)
Sites: Dothan, Alabama; Glendale, Arizona; Little Rock, Arkansas · 45 sites in all
- Treatment of Post-Stroke Central PainRecruiting
Nanchong Central HospitalGovernment (non-federal)
NCT07593313 · 80 participants (planned) · Start Jan 1, 2024 · Primary completion Aug 1, 2029
Drug: Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline) · For: Central Post-Stroke Pain
Sites: Nanchong, China
Second Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT07935408 · 990 participants (planned) · Start Mar 1, 2026 · Primary completion Mar 30, 2029
Drug: Cilostazol-Based Dual Antiplatelet Therapy; Single Antiplatelet Therapy · For: Ischemic Stroke; Symptomatic Intracranial Atherosclerotic Stenosis
Sites: Suzhou, China
- Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic StrokePivotal-lookingRecruiting
Pharmazz, Inc.Industry
NCT05691244 · 514 participants (planned) · Start Jul 24, 2025 · Primary completion Sep 2027
Drug: Drug: Normal Saline; Sovateltide · For: Acute Ischemic Stroke; Cerebral Stroke
Sites: Tucson, Arizona; Carmichael, California; Oxnard, California · 57 sites in all
- Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation StrokePivotal-lookingRecruiting
Shandong Provincial HospitalGovernment (non-federal)
NCT07933692 · 432 participants (planned) · Start Oct 1, 2021 · Primary completion Dec 1, 2026
Drug: Edaravone; Edaravone Dexborneol · For: Acute Ischemic Stroke
Sites: Jinan, China
- Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom OnsetPivotal-lookingRecruiting
Supergene, LLCIndustry
NCT07324837 · 1,050 participants (planned) · Start Jun 9, 2026 · Primary completion Nov 1, 2028
Drug: non-immunogenic staphylokinase; Placebo · For: Ischemic Stroke, Acute
Sites: Ryazan, Russia; Chelyabinsk, Russia; Irkutsk, Russia · 17 sites in all
- Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialPivotal-lookingRecruiting
yifang zhuAcademic, hospital or other
NCT07734792 · 726 participants (planned) · Start Sep 26, 2026 · Primary completion May 31, 2028
Drug: Tirzepatide · For: Acute Ischemic Stroke (AIS)
Sites: Suzhou, China
- Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial StenosisPivotal-lookingRecruiting
Second Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT07932639 · 480 participants (planned) · Start Mar 21, 2026 · Primary completion Feb 28, 2029
Drug: Cilostazol; Aspirin and 2 more · For: Ischemic Stroke; Symptomatic Intracranial Atherosclerotic Stenosis
Sites: Suzhou, China
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseasePivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07839936 · 175 participants (planned) · Start Sep 24, 2026 · Primary completion Aug 2028
Drug: VERVE-102; Placebo · For: Atherosclerosis; Cardiovascular Disease; Hypercholesterolemia
Sites: DeSoto, Texas
- ACT-GLOBAL Adaptive Platform Trial for StrokePivotal-lookingRecruiting
The George InstituteAcademic, hospital or other
NCT06352632 · 20,000 participants (planned) · Start Sep 26, 2024 · Primary completion Sep 2034
Drug: Standard-dose intravenous tenecteplase; Low-dose intravenous tenecteplase and 9 more · For: Stroke
Sites: Sydney, Australia; Calgary, Canada
- A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen WellPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07361302 · 1,325 participants (planned) · Start Feb 17, 2026 · Primary completion Oct 2, 2027
Drug: Tenecteplase; Standard of care treatment · For: Acute Ischemic Stroke
Sites: Buenos Aires, Argentina; Ciudad Autonoma Buenos Aires, Argentina; Córdoba, Argentina · 258 sites in all
- Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy(RECAST-MT)Pivotal-lookingRecruiting
Capital Medical UniversityAcademic, hospital or other
NCT06559241 · 2,105 participants (planned) · Start Sep 23, 2024 · Primary completion Nov 2026
Drug: Best medical management · For: Acute Ischemic Stroke; Anterior Circulation Brain Infarction
Sites: Suzhou, China; Taihe Chengguanzhen, China; Tongling, China · 70 sites in all
- Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR MismatchPivotal-lookingRecruiting
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
NCT07540416 · 564 participants (planned) · Start Nov 2, 2026 · Primary completion Feb 29, 2028
Drug: TNK-tPA; Aspirin and 2 more · For: Acute Ischemic Stroke
Sites: Zhengzhou, China
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2Pivotal-lookingRecruiting
Joseph Broderick, MDAcademic, hospital or other
NCT07227246 · 350 participants (planned) · Start May 6, 2025 · Primary completion Jan 2029
Drug: Recombinant Factor VIIa; Biological/Vaccine: Placebo · For: Intracerebral Hemorrhage
Sites: Birmingham, Alabama; Baldwin Park, California; Burlingame, California · 88 sites in all
- INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical ThrombectomyPivotal-lookingRecruiting
115 People's HospitalGovernment (non-federal)
NCT07727395 · 416 participants (planned) · Start Aug 1, 2026 · Primary completion Dec 31, 2028
Drug: Alteplase · For: Stroke, Acute Ischemic; Large Vessel Occlusion; Thrombectomy
Sites: An Giang, Vietnam; Can Tho, Vietnam; Da Nang, Vietnam · 13 sites in all
- Pemafibrate for Symptomatic ICAS RCTPivotal-lookingRecruiting
Tokyo Women's Medical UniversityAcademic, hospital or other
NCT07562178 · 270 participants (planned) · Start May 26, 2026 · Primary completion Mar 31, 2028
Drug: Pemafibrate · For: Intracranial Atherosclerotic Disease (ICAD); Hypertriglyceridaemia; Stroke (CVA) or TIA
Sites: Toyoake, Japan; Yachiyo, Japan; Yoshida, Japan · 42 sites in all
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07175428 · 1,200 participants (planned) · Start Oct 20, 2025 · Primary completion Feb 9, 2027
Drug: REGN7508; REGN9933 and 1 more · For: Atrial Fibrillation (AF)
Sites: Dothan, Alabama; Fairhope, Alabama; Covina, California · 91 sites in all
- The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke PatientsPivotal-lookingRecruiting
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT07739160 · 340 participants (planned) · Start Sep 29, 2026 · Primary completion Apr 2027
Drug: HRS-4029; Placebo · For: Acute Ischemic Stroke
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.